thromboplastin and Genital-Neoplasms--Female

Antibody drug conjugates (ADCs) are an exciting class of oncologic therapeutics. ADCs have been FDA approved in hematologic malignancies and breast cancer and are a growing area of study in numerous solid malignancies. The desire for tumor-specific therapies with decreased systemic toxicity has driven over a decade of research into the design and optimization of ADCs, which are now in a third generation of development. Gynecologic malignancies in particular suffer a dearth of novel therapies. This review will examine the field of ADCs in gynecologic cancers, focusing on ADCs targeting folate receptor alpha (FRα), mesothelin, tissue factor, MUC16 (CA125), NaPi2B, and Trop2.

Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; CA-125 Antigen; Camptothecin; Cell Adhesion Molecules; Drug Design; Female; Folate Receptor 1; Genital Neoplasms, Female; GPI-Linked Proteins; Humans; Immunoconjugates; Maytansine; Membrane Proteins; Mesothelin; Sodium-Phosphate Cotransporter Proteins, Type IIb; Thromboplastin

Under study were coagulation and fibrinolytic properties of cancerous tumor, their role in the ethiopathogenesis of thromb-formation is defined. It was found that the cervical tissue involved contains a large quantity of thromboplastic substances and shows an intense antiheparin, antithrombin and antifibrinolytic activity.

Topics: Blood Coagulation; Blood Coagulation Disorders; Cervix Uteri; Female; Fibrinolysis; Genital Neoplasms, Female; Humans; Thromboplastin; Thrombosis